Gene GMS 01

ABSTRACT

The present invention relates to microorganisms genetically engineered to increase yield and/or efficiency of biomass production from a carbon source, such as e.g. glucose. Processes for generating such microorganisms are also provided by the present invention. The invention also relates to polynucleotide sequences comprising genes that encode proteins that are involved in the bioconversion of a carbon source such as e.g. glucose into biomass. The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. Also included are processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms leading to a microorganism with reduced carbon source diversion, i.e. higher yield and/or efficiency of biomass production from a carbon source such as e.g. glucose.

This application is a continuation of U.S. application Ser. No.11/991,427, filed Apr. 18, 2008, now abandoned which is the U.S.national phase under 35 USC 371 of Int'l Application No.PCT/EP2006/008729, filed Sep. 7, 2006, which designated the U.S. andclaims priority to European Patent Application No. 05021383.4, filed 9Sep. 2005; the entire contents of each of which are hereby incorporatedby reference.

The present invention relates to microorganisms genetically engineeredto increase yield and/or efficiency of biomass production from a carbonsource, such as e.g. glucose. Processes for generating suchmicroorganisms are also provided by the present invention. The inventionalso relates to polynucleotide sequences comprising genes that encodeproteins that are involved in the bioconversion of a carbon source suchas e.g. glucose into biomass. The invention also featurespolynucleotides comprising the full-length polynucleotide sequences ofthe novel genes and fragments thereof, the novel polypeptides encoded bythe polynucleotides and fragments thereof, as well as their functionalequivalents. Also included are processes of using the polynucleotidesand modified polynucleotide sequences to transform host microorganismsleading to a microorganism with reduced carbon source diversion, i.e.higher yield and/or efficiency of biomass production from a carbonsource such as e.g. glucose.

The bioconversion of a carbon source may involve many differentmetabolic routes, and involve several enzymatic steps to generatebiomass, wherein the enzymes may be located in the cytosol, on themembrane or in the periplasmic space of a host cell. Furthermore,transporters may also play an important role in the efficient conversionof a carbon source into biomass.

For instance, in the case of acetic acid bacteria, which are obligateaerobe, gram-negative microorganisms belonging to the genus Acetobacter,Gluconobacter, and Gluconacetobacter, these microorganisms are able tooxidize D-glucose at the periplasmic membrane level to D-gluconate bymeans of a membrane-bound D-glucose dehydrogenase, and transportD-gluconate into the cytosol. D-gluconate can then be phosphorylated bygluconokinase to D-gluconate-6-phosphate. In addition to that, it isbelieved that D-glucose can be directly transported into the cytosol andthen converted into D-gluconate by means of a cytosolic NAD(P)-dependentD-glucose dehydrogenase. Furthermore, D-glucose transported into thecytosol can also be first phosphorylated to D-glucose-6-phosphate byglucokinase and then be dehydrogenated to D-gluconate-6-phosphate.D-gluconate-6-phosphate may enter the pentose phosphate pathway, beingfurther metabolized to produce reducing power in the form of NAD(P)H andtricarboxylic compounds necessary for growth and maintenance.

Proteins, in particular enzymes, that are active in the metabolizationof glucose are herein referred to as being involved in the GlucoseMetabolization System. Such proteins are abbreviated herein as GMSproteins and function in the direct metabolization or bioconversion of acarbon source such as e.g. glucose into biomass.

One disadvantage of such bioconversion processes, however, is thediversion of carbon sources or intermediates throughout saidbioconversion process such that for instance the next (enzymatic) stepcannot be performed in an optimal way, leading to the loss of availablecarbon substrate material for conversion into biomass and resultantenergy losses, in form of e.g. ATP or NADPH. In the case of for instancethe bioconversion of glucose into biomass, this loss may be due totransporting the glucose or an intermediate thereof out of the cytosolor by using the glucose or the resulting intermediates as substrates forother pathways not leading to the production of biomass.

It is an object of the present invention to provide microorganisms whichare engineered in such a way that the carbon source diversion throughoutthe bioconversion of carbon sources, such as e.g. glucose, is altered,e.g. via reduction of carbon source diversion, leading to higherproduction and/or yield of biomass produced from such carbon sources.

Surprisingly, it has now been found that GMS proteins or subunits ofsuch proteins having activity towards or which are involved in thebioconversion of a carbon source such as e.g. glucose play an importantrole in the production of biomass.

In one embodiment, GMS proteins of the present invention are selectedfrom oxidoreductases [EC 1], preferably oxidoreductases acting on theCH—OH group of donors [EC 1.1], more preferably oxidoreductases withNAD⁺ or NADP⁺ as acceptor [EC 1.1.1] and oxidoreductases with a quinoneor similar compound as acceptor [EC 1.1.5], most preferably NADP-glucosedehydrogenase [EC 1.1.1.47] and PQQ dependent glucose dehydrogenase [EC1.1.5.2] or from transferases [EC 2], preferably transferasestransferring phosphorus-containing groups [EC 2.7], more preferablyphosphotransferases with an alcohol group as acceptor [EC 2.7.1], mostpreferably gluconokinase [EC 2.7.1.12].

Furthermore, the GMS proteins or subunits of such proteins havingactivity towards or which are involved in the bioconversion of a carbonsource such as e.g. glucose into biomass are selected from the groupconsisting of membrane-bound PQQ-dependent D-glucose dehydrogenase,NAD(P)-dependent D-glucose dehydrogenase, cytosolic D-glucose kinase,enzymes or enzyme subunits having activity towards or involved in theassimilation of D-gluconate such as membrane-bound FAD-dependentD-gluconate dehydrogenase (2-keto-D-gluconate-forming), membrane-boundPQQ-dependent D-gluconate dehydrogenase (5-keto-D-gluconate-forming),cytosolic D-gluconate kinase, enzymes or enzyme subunits having activitytowards or involved in the assimilation of 2KD such as membrane-boundFAD-dependent 2-keto-D-gluconate dehydrogenase, NAD(P)-dependentglucose-1-dehydrogenase, flavin containing gluconate-2-dehydrogenase,gluconate-5-dehydrogenase (5-keto-D-gluconate reductase), and cytosolicNAD(P)-dependent 2-keto-D-gluconate reductase.

In particular, it has now been found that GMS proteins encoded bypolynucleotides having a nucleotide sequence that hybridizes preferablyunder highly stringent conditions to a sequence shown in SEQ ID NO:1play an important role in the bioconversion of a carbon source such ase.g. glucose to biomass. It has also been found, that by geneticallyaltering such nucleotides in a microorganism, such as for exampleGluconobacter, the efficiency of said bioconversion within saidmicroorganism can be even greatly improved leading e.g. to higherproduction and/or yield of biomass from a carbon source such as e.g.glucose.

Consequently, the invention relates to a polynucleotide selected fromthe group consisting of:

(a) polynucleotides encoding a polypeptide comprising the amino acidsequence according to SEQ ID NO:2;

(b) polynucleotides comprising the nucleotide sequence according to SEQID NO:1;

(c) polynucleotides comprising a nucleotide sequence obtainable bynucleic acid amplification such as polymerase chain reaction, usinggenomic DNA from a microorganism as a template and a primer setaccording to SEQ ID NO:3 and SEQ ID NO:4;

(d) polynucleotides Comprising a nucleotide sequence encoding a fragmentor derivative of a polypeptide encoded by a polynucleotide of any of (a)to (c) wherein in said derivative one or more amino acid residues areconservatively substituted compared to said polypeptide, and saidfragment or derivative has the activity of an oxidoreductase [EC 1],preferably an oxidoreductase acting on the CH—OH group of donors [EC1.1] (GMS 01);(e) polynucleotides the complementary strand of which hybridizes understringent conditions to a polynucleotide as defined in any one of (a) to(d) and which encode an oxidoreductase [EC 1], preferably anoxidoreductase acting on the CH—OH group of donors [EC 1.1] (GMS 01);and(f) polynucleotides which are at least 70%, such as 85, 90 or 95%homologous to a polynucleotide as defined in any one of (a) to (d) andwhich encode an oxidoreductase [EC 1], preferably an oxidoreductaseacting on the CH—OH group of donors [EC 1.1] (GMS 01);orthe complementary strand of such a polynucleotide.

The GMS protein as isolated from Gluconobacter oxydans DSM 17078 shownin SEQ ID NO:2 and described herein was found to be particularly useful,since the gene encoding said GMS protein appeared to perform a crucialfunction in the bioconversion of a carbon source such as e.g. glucose tobiomass in microorganisms, in particular in bacteria, such as aceticacid bacteria, such as Gluconobacter, Acetobacter and Gluconacetobacter.Accordingly, the invention relates to a polynucleotide encoding apolypeptide according to SEQ ID NO:2. This protein may be encoded by anucleotide sequence as shown in SEQ ID NO:1. The invention thereforealso relates to polynucleotides comprising the nucleotide sequenceaccording to SEQ ID NO:1.

The nucleotide and amino acid sequences determined above were used as a“query sequence” to perform a search with Blast2 program (version 2 orBLAST from National Center for Biotechnology [NCBI] against the databasePRO SW-SwissProt (full release plus incremental updates). From thesearches, the GMS 01 polynucleotide according to SEQ ID NO:1 wasannotated as encoding a protein having membrane-bound PQQ-dependentglucose dehydrogenase activity.

A nucleic acid according to the invention may be obtained by nucleicacid amplification using cDNA, mRNA or alternatively, genomic DNA, as atemplate and appropriate oligonucleotide primers such as the nucleotideprimers according to SEQ ID NO:3 and SEQ ID NO:4 according to standardPCR amplification techniques. The nucleic acid thus amplified may becloned into an appropriate vector and characterized by DNA sequenceanalysis.

The template for the reaction may be cDNA obtained by reversetranscription of mRNA prepared from strains known or suspected tocomprise a polynucleotide according to the invention. The PCR productmay be subcloned and sequenced to ensure that the amplified sequencesrepresent the sequences of a new nucleic acid sequence as describedherein, or a functional equivalent thereof.

The PCR fragment may then be used to isolate a full length cDNA clone bya variety of known methods. For example, the amplified fragment may belabeled and used to screen a bacteriophage or cosmid cDNA library.Alternatively, the labeled fragment may be used to screen a genomiclibrary.

Accordingly, the invention relates to polynucleotides comprising anucleotide sequence obtainable by nucleic acid amplification such aspolymerase chain reaction, using DNA such as genomic DNA from amicroorganism as a template and a primer set according to SEQ ID NO:3and SEQ ID NO:4.

The invention also relates to polynucleotides comprising a nucleotidesequence encoding a fragment or derivative of a polypeptide encoded by apolynucleotide as described herein wherein in said derivative one ormore amino acid residues are conservatively substituted compared to saidpolypeptide, and said fragment or derivative has the activity of a GMSpolypeptide, preferably a GMS 01 polypeptide.

The invention also relates to polynucleotides the complementary strandof which hybridizes under stringent conditions to a polynucleotide asdefined herein and which encode a GMS polypeptide, preferably a GMS 01polypeptide.

The invention also relates to polynucleotides which are at least 70%identical to a polynucleotide as defined herein and which encode a GMSpolypeptide; and the invention also relates to polynucleotides being thecomplementary strand of a polynucleotide as defined herein above.

The invention also relates to primers, probes and fragments that may beused to amplify or detect a DNA according to the invention and toidentify related species or families of microorganisms also carryingsuch genes.

The present invention also relates to vectors which includepolynucleotides of the invention and microorganisms which aregenetically engineered with the polynucleotides or said vectors.

The invention also relates to processes for producing microorganismscapable of expressing a polypeptide encoded by the above definedpolynucleotide and a polypeptide encoded by a polynucleotide as definedabove.

The invention also relates to microorganisms wherein the activity of aGMS polypeptide, preferably a GMS 01 polypeptide, is reduced orabolished so that the yield and/or production of biomass which isproduced through bioconversion of a carbon source such as e.g. glucoseis increased.

A suitable carbon source that can be converted into biomass may be forinstance glucose or selected from carbon sources the assimilation ofwhich results in the formation of glucose, in particular D-glucose, suchas sucrose, maltose, starch, cellulose, cellobiose, lactose, isomaltose,dextran, trehalose or mixtures thereof.

The skilled person will know how to reduce or abolish the activity of aGMS protein, preferably a GMS 01 protein. Such may be for instanceaccomplished by either genetically modifying the host organism in such away that it produces less or no copies of the GMS protein, preferablythe GMS 01 protein, than the wild type organism or by decreasing orabolishing the specific activity of the GMS protein, preferably the GMS01 protein.

In the following description, procedures are detailed to achieve thisgoal, i.e. the increase in the yield and/or production of biomass whichis produced through bioconversion of a carbon source such as e.g.glucose by reducing or abolishing the activity of a GMS 01 protein.These procedures apply mutatis mutandis for other GMS proteins.

Modifications in order to have the organism produce less or no copies ofthe GMS 01 gene and/or protein may include the use of a weak promoter,or the mutation (e.g. insertion, deletion or point mutation) of (partsof) the GMS 01 gene or its regulatory elements. Decreasing or abolishingthe specific activity of a GMS 01 protein may also be accomplished bymethods known in the art. Such methods may include the mutation (e.g.insertion, deletion or point mutation) of (parts of) the GMS 01 gene.

Also known in the art are methods of reducing or abolishing the activityof a given protein by contacting the GMS 01 protein with specificinhibitors or other substances that specifically interact with the GMS01 protein. In order to identify such specific inhibitors, the GMS 01protein may be expressed and tested for activity in the presence ofcompounds suspected to inhibit the activity of the GMS 01 protein.Potential inhibiting compounds may for instance be monoclonal orpolyclonal antibodies against the GMS 01 protein. Such antibodies may beobtained by routine immunization protocols of suitable laboratoryanimals.

The invention may be performed in any microorganism carrying a GMS 01gene or equivalent or homologue thereof. Suitable microorganisms may beselected from the group consisting of yeast, algae and bacteria, eitheras wild type strains, mutant strains derived by classic mutagenesis andselection methods or as recombinant strains. Examples of such yeast maybe, e.g., Candida, Saccharomyces, Zygosaccharomyces,Schizosaccharomyces, or Kluyveromyces. An example of such algae may be,e.g., Chlorella. Examples of such bacteria may be, e.g., Gluconobacter,Acetobacter, Gluconacetobacter, Ketogulonicigenium, Pantoea,Pseudomonas, such as, e.g., Pseudomonas putida, and Escherichia, suchas, e.g., Escherichia coli. Preferred are Gluconobacter or Acetobacteraceti, such as for instance G. oxydans, G. cerinus, G. frateurii, A.aceti subsp. xylinum or A. aceti subsp. orleanus, preferably G. oxydansDSM 17078. Gluconobacter oxydans DSM 17078 (formerly known asGluconobacter oxydans N44-1) has been deposited at Deutsche Sammlung vonMikroorganismen und Zellkulturen (DSMZ), Mascheroder Weg 1B, D-38124Braunschweig, Germany according to the Budapest Treaty on 26. Jan. 2005.

Microorganisms which can be used for the present invention may bepublicly available from different sources, e.g., Deutsche Sammlung vonMikroorganismen und Zellkulturen (DSMZ), Mascheroder Weg 1B, D-38124Braunschweig, Germany, American Type Culture Collection (ATCC), P.O. Box1549, Manassas, Va. 20108 USA or Culture Collection Division, NITEBiological Resource Center, 2-5-8, Kazusakamatari, Kisarazu-shi, Chiba,292-0818, Japan (formerly: Institute for Fermentation, Osaka (IFO),17-85, Juso-honmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan).Examples of preferred bacteria deposited with IFO are for instanceGluconobacter oxydans (formerly known as G. melanogenus) IFO 3293,Gluconobacter oxydans (formerly known as G. melanogenus) IFO 3292,Gluconobacter oxydans (formerly known as G. rubiginosus) IFO 3244,Gluconobacter frateurii (formerly known as G. industrius) IFO 3260,Gluconobacter cerinus IFO 3266, Gluconobacter oxydans IFO 3287, andAcetobacter aceti subsp. orleanus IFO 3259, which were all deposited onApr. 5, 1954; Acetobacter aceti subsp. xylinum IFO 13693 deposited onOct. 22, 1975, and Acetobacter aceti subsp. xylinum IFO 13773 depositedon Dec. 8, 1977. Strain Acetobacter sp. ATCC 15164, which is also anexample of a preferred bacterium, was deposited with ATCC. StrainGluconobacter oxydans (formerly known as G. melanogenus) N 44-1 asanother example of a preferred bacterium is a derivative of the strainIFO 3293 and is described in Sugisawa et al., Agric. Biol. Chem. 54:1201-1209, 1990.

A microorganism as of the present invention may carry furthermodifications either on the DNA or protein level (see above), as long assuch modification(s) has/have a direct impact on the yield, productionand/or efficiency of biomass from a substrate such as e.g. glucose. Suchfurther modifications may for instance affect other genes encodingoxidoreductases or isomerases as described above, in particular genesencoding NAD(P)-glucose dehydrogenase, PQQ-dependent glucosedehydrogenase, FAD-dependent gluconate-2-dehydrogenase,NAD(P)-gluconate-2-dehydrognease, gluconate-5-dehydrogenase,2-ketogluconate dehydrogenase, 2,5-di-ketogluconate dehydrogenase,gluconate oxidase, phosphoglucoseisomerase, or further genes encodingenzymes involved in the pentose phosphate pathway, such as for instance6-phosphogluconate dehydrogenase, 6-phosphogluconolactonase,ribulose-5-phosphate 3-epimerase, transaldolase or transketolase, orfurther genes encoding enzymes linking the pentose phosphate pathway toother pathways of carbon metabolism, such as for instance6-phosphogluconate dehydratase, fructose-1,6-bisphosphate orphosphofructokinase. Methods of performing such modifications are knownin the art, with some examples further described herein.

In accordance with a further object of the present invention there isprovided the use of a polynucleotide as defined above or a microorganismwhich is genetically engineered using such polynucleotides in theefficient production of biomass from a carbon source.

The invention also relates to processes for the expression of endogenousgenes in a microorganism, to processes for the production ofpolypeptides as defined above in a microorganism and to processes forthe production of microorganisms capable of growth on a given carbonsource such as e.g. glucose. All these processes comprise the step ofaltering a microorganism, wherein “altering” as used herein encompassesthe process for “genetically altering” or “altering the composition ofthe cell culture media and/or methods used for culturing” in such a waythat the yield and/or productivity of biomass can be improved comparedto the wild-type organism. As used herein, “improved yield of biomass”means an increase of at least 5%, 10%, 25%, 30%, 40%, 50%, 75%, 100%,200% or even more than 500%, depending on the carbon source used forgrowth, compared to a wild-type microorganism, i.e. a microorganismwhich is not genetically altered.

The term “genetically engineered” or “genetically altered” means thescientific alteration of the structure of genetic material in a livingorganism. It involves the production and use of recombinant DNA. More inparticular it is used to delineate the genetically engineered ormodified organism from the naturally occurring organism. Geneticengineering may be done by a number of techniques known in the art, suchas e.g. gene replacement, gene amplification, gene disruption,transfection, transformation using plasmids, viruses, or other vectors.A genetically modified organism, e.g. genetically modifiedmicroorganism, is also often referred to as a recombinant organism, e.g.recombinant microorganism.

Advantageous embodiments of the invention become evident from thedependent claims. These and other aspects and embodiments of the presentinvention should now be apparent to those skilled in the art based onthe teachings herein.

The sequence of the gene comprising a nucleotide sequence according toSEQ ID NO:1 encoding a GMS 01 protein was determined by sequencing agenomic clone obtained from Gluconobacter oxydans DSM 17078.

The invention also relates to a polynucleotide encoding at least abiologically active fragment or derivative of a GMS 01 polypeptide asshown in SEQ ID NO:2.

As used herein, “biologically active fragment or derivative” means apolypeptide which retains essentially the same biological function oractivity as the polypeptide shown in SEQ ID NO:2. Examples of biologicalactivity may for instance be enzymatic activity, signaling activity orantibody reactivity activity. The term “biological function” or“functional equivalent” as used herein means that the protein hasessentially the same biological activity, e.g. enzymatic, signaling orantibody reactivity activity, as a polypeptide shown in SEQ ID NO:2.

The polypeptides and polynucleotides of the present invention arepreferably provided in an isolated form, and preferably are purified tohomogeneity.

The term “isolated” means that the material is removed from its originalenvironment (e.g., the natural environment if it is naturallyoccurring). For example, a naturally-occurring polynucleotide orpolypeptide present in a living microorganism is not isolated, but thesame polynucleotide or polypeptide, separated from some or all of thecoexisting materials in the natural system, is isolated. Suchpolynucleotides could be part of a vector and/or such polynucleotides orpolypeptides could be part of a composition and still be isolated inthat such vector or composition is not part of its natural environment.

An isolated polynucleotide or nucleic acid as used herein may be a DNAor RNA that is not immediately contiguous with both of the codingsequences with which it is immediately contiguous (one on the 5′-end andone on the 3′-end) in the naturally occurring genome of the organismfrom which it is derived. Thus, in one embodiment, a nucleic acidincludes some or all of the 5′-non-coding (e.g., promoter) sequencesthat are immediately contiguous to the coding sequence. The term“isolated polynucleotide” therefore includes, for example, a recombinantDNA that is incorporated into a vector, into an autonomously replicatingplasmid or virus, or into the genomic DNA of a prokaryote or eukaryote,or which exists as a separate molecule (e.g., a cDNA or a genomic DNAfragment produced by PCR or restriction endonuclease treatment)independent of other sequences. It also includes a recombinant DNA thatis part of a hybrid gene encoding an additional polypeptide that issubstantially free of cellular material, viral material, or culturemedium (when produced by recombinant DNA techniques), or chemicalprecursors or other chemicals (when chemically synthesized). Moreover,an “isolated nucleic acid fragment” is a nucleic acid fragment that isnot naturally occurring as a fragment and would not be found in thenatural state.

As used herein, the terms “polynucleotide”, “gene” and “recombinantgene” refer to nucleic acid molecules which may be isolated fromchromosomal DNA, which include an open reading frame encoding a protein,e.g. G. oxydans DSM 17078 GMS proteins. A polynucleotide may include apolynucleotide sequence as shown in SEQ ID NO:1 or fragments thereof andregions upstream and downstream of the gene sequences which may include,for example, promoter regions, regulator regions and terminator regionsimportant for the appropriate expression and stabilization of thepolypeptide derived thereof.

A gene may include coding sequences, non-coding sequences such as forinstance untranslated sequences located at the 3′- and 5′-ends of thecoding region of a gene, and regulatory sequences. Moreover, a generefers to an isolated nucleic acid molecule as defined herein. It isfurthermore appreciated by the skilled person that DNA sequencepolymorphisms that lead to changes in the amino acid sequences of GMSproteins may exist within a population, e.g., the Gluconobacter oxydanspopulation. Such genetic polymorphism in the GMS 01 gene may exist amongindividuals within a population due to natural variation or in cellsfrom different populations. Such natural variations can typically resultin 1-5% variance in the nucleotide sequence of the GMS 01 gene. Any andall such nucleotide variations and the resulting amino acid polymorphismin GMS 01 are the result of natural variation and that do not alter thefunction or biological activity of GMS proteins are intended to bewithin the scope of the invention.

As used herein, the terms “polynucleotide” or “nucleic acid molecule”are intended to include DNA molecules (e.g., cDNA or genomic DNA) andRNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated usingnucleotide analogs. The nucleic acid molecule may be single-stranded ordouble-stranded, but preferably is double-stranded DNA. The nucleic acidmay be synthesized using oligonucleotide analogs or derivatives (e.g.,inosine or phosphorothioate nucleotides). Such oligonucleotides may beused, for example, to prepare nucleic acids that have alteredbase-pairing abilities or increased resistance to nucleases.

The sequence information as provided herein should not be so narrowlyconstrued as to require inclusion of erroneously identified bases. Thespecific sequences disclosed herein may be readily used to isolate thecomplete gene from a microorganism capable of converting a given carbonsource such as e.g. glucose into biomass, in particular Gluconobacteroxydans, preferably Gluconobacter oxydans DSM 17078 which in turn mayeasily be subjected to further sequence analyses thereby identifyingsequencing errors.

Unless otherwise indicated, all nucleotide sequences determined bysequencing a DNA molecule herein were determined using an automated DNAsequencer and all amino acid sequences of polypeptides encoded by DNAmolecules determined herein were predicted by translation of a DNAsequence determined as above. Therefore, as is known in the art for anyDNA sequence determined by this automated approach, any nucleotidesequence determined herein may contain some errors. Nucleotide sequencesdetermined by automation are typically at least about 90% identical,more typically at least about 95% to at least about 99.9% identical tothe actual nucleotide sequence of the sequenced DNA molecule. The actualsequence may be more precisely determined by other approaches includingmanual DNA sequencing methods well known in the art. As is also known inthe art, a single insertion or deletion in a determined nucleotidesequence compared to the actual sequence will cause a frame shift intranslation of the nucleotide sequence such that the predicted aminoacid sequence encoded by a determined nucleotide sequence will becompletely different from the amino acid sequence actually encoded bythe sequenced DNA molecule, beginning at the point of such an insertionor deletion.

The person skilled in the art is capable of identifying such erroneouslyidentified bases and knows how to correct for such errors.

A nucleic acid molecule according to the invention may comprise only aportion or a fragment of the nucleic acid sequence provided by thepresent invention, such as for instance the sequence shown in SEQ IDNO:1, for example a fragment which may be used as a probe or primer suchas for instance SEQ ID NO:3 or SEQ ID NO:4 or a fragment encoding aportion of a protein according to the invention. The nucleotide sequencedetermined from the cloning of the GMS 01 gene allows for the generationof probes and primers designed for use in identifying and/or cloningother GMS 01 family members, as well as GMS 01 homologues from otherspecies. The probe/primer typically comprises substantially purifiedoligonucleotides which typically comprises a region of nucleotidesequence that hybridizes preferably under highly stringent conditions toat least about 12 or 15, preferably about 18 or 20, more preferablyabout 22 or 25, even more preferably about 30, 35, 40, 45, 50, 55, 60,65, or 75 or more consecutive nucleotides of a nucleotide sequence shownin SEQ ID NO:1 or a fragment or derivative thereof.

A nucleic acid molecule encompassing all or a portion of the nucleicacid sequence of SEQ ID NO:1 may be isolated by the polymerase chainreaction (PCR) using synthetic oligonucleotide primers designed basedupon the sequence information contained herein.

A nucleic acid of the invention may be amplified using cDNA, mRNA oralternatively, genomic DNA, as a template and appropriateoligonucleotide primers according to standard PCR amplificationtechniques. The nucleic acid thus amplified may be cloned into anappropriate vector and characterized by DNA sequence analysis.

Fragments of a polynucleotide according to the invention may alsocomprise polynucleotides not encoding functional polypeptides. Suchpolynucleotides may function as probes or primers for a PCR reaction.

Nucleic acids according to the invention irrespective of whether theyencode functional or non-functional polypeptides, may be used ashybridization probes or polymerase chain reaction (PCR) primers. Uses ofthe nucleic acid molecules of the present invention that do not encode apolypeptide having a GMS 01 activity include, inter alia, (1) isolatingthe gene encoding the protein of the present invention, or allelicvariants thereof from a cDNA library, e.g., from other organisms thanGluconobacter oxydans and (2) Northern blot analysis for detectingexpression of mRNA of said protein in specific cells or (3) use inabolishing or altering the function or activity of homologous GMS 01genes in said other organisms.

Probes based on the nucleotide sequences provided herein may be used todetect transcripts or genomic sequences encoding the same or homologousproteins for instance in other organisms. Nucleic acid moleculescorresponding to natural variants and non-G. oxydans homologues of theG. oxydans GMS 01 DNA of the invention which are also embraced by thepresent invention may be isolated based on their homology to the G.oxydans GMS 01 nucleic acid disclosed herein using the G. oxydans DNA,or a portion thereof, as a hybridization probe according to standardhybridization techniques, preferably under highly stringenthybridization conditions.

In preferred embodiments, the probe further comprises a label groupattached thereto, e.g., the label group can be a radioisotope, afluorescent compound, an enzyme, or an enzyme cofactor.

Homologous gene sequences may be isolated, for example, by performingPCR using two degenerate oligonucleotide primer pools designed on thebasis of nucleotide sequences as taught herein.

The template for the reaction may be cDNA obtained by reversetranscription of mRNA prepared from strains known or suspected toexpress a polynucleotide according to the invention. The PCR product maybe subcloned and sequenced to ensure that the amplified sequencesrepresent the sequences of a new nucleic acid sequence as describedherein, or a functional equivalent thereof.

The PCR fragment may then be used to isolate a full length cDNA clone bya variety of known methods. For example, the amplified fragment may belabeled and used to screen a bacteriophage or cosmid cDNA library.Alternatively, the labeled fragment may be used to screen a genomiclibrary.

PCR technology can also be used to isolate full-length cDNA sequencesfrom other organisms. For example, RNA may be isolated, followingstandard procedures, from an appropriate cellular or tissue source. Areverse transcription reaction may be performed on the RNA using anoligonucleotide primer specific for the most 5′-end of the amplifiedfragment for the priming of first strand synthesis.

The resulting RNA/DNA hybrid may then be “tailed” (e.g., with guanines)using a standard terminal transferase reaction, the hybrid may bedigested with RNaseH, and second strand synthesis may then be primed(e.g., with a poly-C primer). Thus, cDNA sequences upstream of theamplified fragment may easily be isolated. For a review of usefulcloning strategies, see e.g., Sambrook et al., supra; and Ausubel etal., supra.

Also, nucleic acids encoding other GMS 01 family members, which thushave a nucleotide sequence that differs from a nucleotide sequenceaccording to SEQ ID NO:1, are within the scope of the invention.Moreover, nucleic acids encoding GMS 01 proteins from different specieswhich thus may have a nucleotide sequence which differs from anucleotide sequence shown in SEQ ID NO:1 are within the scope of theinvention.

The invention also relates to an isolated polynucleotide hybridisableunder stringent conditions, preferably under highly stringentconditions, to a polynucleotide according to the present invention, suchas for instance a polynucleotide shown in SEQ ID NO:1. Advantageously,such polynucleotide may be obtained from a microorganism capable ofconverting a given carbon source such as e.g. glucose into biomass, inparticular Gluconobacter oxydans, preferably Gluconobacter oxydans DSM17078.

As used herein, the term “hybridizing” is intended to describeconditions for hybridization and washing under which nucleotidesequences at least about 50%, at least about 60%, at least about 70%,more preferably at least about 80%, even more preferably at least about85% to 90%, most preferably at least 95% homologous to each othertypically remain hybridized to each other.

In one embodiment, a nucleic acid of the invention is at least 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99%, or more homologous to a nucleic acid sequence shownin SEQ ID NO:1 or the complement thereof.

A preferred; non-limiting example of such hybridization conditions arehybridization in 6× sodium chloride/sodium citrate (SSC) at about 45°C., followed by one or more washes in 1×SSC, 0.1% SDS at 50° C.,preferably at 55° C., more preferably at 60° C. and even more preferablyat 65° C.

Highly stringent conditions include, for example, 2 h to 4 daysincubation at 42° C. using a digoxigenin (DIG)-labeled DNA probe(prepared by using a DIG labeling system; Roche Diagnostics GmbH, 68298Mannheim, Germany) in a solution such as DigEasyHyb solution (RocheDiagnostics GmbH) with or without 100 μg/ml salmon sperm DNA, or asolution comprising 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodiumcitrate), 0.02% sodium dodecyl sulfate, 0.1% N-lauroylsarcosine, and 2%blocking reagent (Roche Diagnostics GmbH), followed by washing thefilters twice for 5 to 15 minutes in 2×SSC and 0.1% SDS at roomtemperature and then washing twice for 15-30 minutes in 0.5×SSC and 0.1%SDS or 0.1×SSC and 0.1% SDS at 65-68° C.

Preferably, an isolated nucleic acid molecule of the invention thathybridizes under preferably highly stringent conditions to a nucleotidesequence of the invention corresponds to a naturally-occurring nucleicacid molecule. As used herein, a “naturally-occurring” nucleic acidmolecule refers to an RNA or DNA molecule having a nucleotide sequencethat occurs in nature (e.g., encodes a natural protein). In oneembodiment, the nucleic acid encodes a natural G. oxydans GMS 01protein.

The skilled artisan will know which conditions to apply for stringentand highly stringent hybridization conditions. Additional guidanceregarding such conditions is readily available in the art, for example,in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, ColdSpring Harbor Press, N.Y.; and Ausubel et al. (eds.), 1995, CurrentProtocols in Molecular Biology, (John Wiley & Sons, N.Y.). Of course, apolynucleotide which hybridizes only to a poly (A) sequence (such as the3′-terminal poly (A) tract of mRNAs), or to a complementary stretch of T(or U) residues, would not be included in a polynucleotide of theinvention used to specifically hybridize to a portion of a nucleic acidof the invention, since such a polynucleotide would hybridize to anynucleic acid molecule containing a poly (A) stretch or the complementthereof (e.g., practically any double-stranded cDNA clone).

In a typical approach, genomic DNA or cDNA libraries constructed fromother organisms, e.g. microorganisms capable of converting of a givencarbon source such as e.g. glucose into biomass, in particular otherGluconobacter species may be screened.

For example, Gluconobacter strains may be screened for homologouspolynucleotides by Northern blot analysis. Upon detection of transcriptshomologous to polynucleotides according to the invention, DNA librariesmay be constructed from RNA isolated from the appropriate strain,utilizing standard techniques well known to those of skill in the art.Alternatively, a total genomic DNA library may be screened using a probehybridisable to a polynucleotide according to the invention.

A nucleic acid molecule of the present invention, such as for instance anucleic acid molecule shown in SEQ ID NO:1 or a fragment or derivativethereof, may be isolated using standard molecular biology techniques andthe sequence information provided herein. For example, using all orportion of the nucleic acid sequence shown in SEQ ID NO:1 as ahybridization probe, nucleic acid molecules according to the inventionmay be isolated using standard hybridization and cloning techniques(e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T.Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring HarborLaboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,N.Y., 1989).

Furthermore, oligonucleotides corresponding to or hybridisable tonucleotide sequences according to the invention may be prepared bystandard synthetic techniques, e.g., using an automated DNA synthesizer.

The terms “homology” or “percent identity” are used interchangeablyherein. For the purpose of this invention, it is defined here that inorder to determine the percent identity of two amino acid sequences orof two nucleic acid sequences, the sequences are aligned for optimalcomparison purposes (e.g., gaps may be introduced in the sequence of afirst amino acid or nucleic acid sequence for optimal alignment with asecond amino or nucleic acid sequence). The amino acid residues ornucleotides at corresponding amino acid positions or nucleotidepositions are then compared. When a position in the first sequence isoccupied by the same amino acid residue or nucleotide as thecorresponding position in the second sequence, then the molecules areidentical at that position. The percent identity between the twosequences is a function of the number of identical positions shared bythe sequences (i.e., % identity=number of identical positions/totalnumber of positions (i.e., overlapping positions)×100). Preferably, thetwo sequences are the same length.

The skilled person will be aware of the fact that several differentcomputer programs are available to determine the homology between twosequences. For instance, a comparison of sequences and determination ofpercent identity between two sequences may be accomplished using amathematical algorithm. In a preferred embodiment, the percent identitybetween two amino acid sequences is determined using the Needleman andWunsch (J. Mol. Biol. (48): 444-453 (1970)) algorithm which has beenincorporated into the GAP program in the GCG software package (availableat http://www.accelrys.com), using either a Blossom 62 matrix or aPAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6 or 4 and alength weight of 1, 2, 3, 4, 5 or 6. The skilled person will appreciatethat all these different parameters will yield slightly differentresults but that the overall percentage identity of two sequences is notsignificantly altered when using different algorithms.

In yet another embodiment, the percent identity between two nucleotidesequences is determined using the GAP program in the GCG softwarepackage (available at http://www.accelrys.com), using a NWSgapdna.CMPmatrix and a gap weight of 40, 50, 60, 70 or 80 and a length weight of1, 2, 3, 4, 5 or 6. In another embodiment, the percent identity betweentwo amino acid or nucleotide sequences is determined using the algorithmof E. Meyers and W. Miller (CABIOS, 4: 11-17 (1989) which has beenincorporated into the ALIGN program (version 2.0) (available athttp://vega.igh.cnrs.fr/bin/align-guess.cgi) using a PAM120 weightresidue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention mayfurther be used as a “query sequence” to perform a search against publicdatabases to, for example, identify other family members or relatedsequences. Such searches may be performed using the BLASTN and BLASTXprograms (version 2.0) of Altschul, et al. (1990) J. Mol. Biol.215:403-10. BLAST nucleotide searches may be performed with the BLASTNprogram, score=100, word length=12 to obtain nucleotide sequenceshomologous to the nucleic acid molecules of the present invention. BLASTprotein searches may be performed with the BLASTX program, score=50,word length=3 to obtain amino acid sequences homologous to the proteinmolecules of the present invention. To obtain gapped alignments forcomparison purposes, Gapped BLAST may be utilized as described inAltschul et al., (1997) Nucleic Acids Res. 25 (17): 3389-3402. Whenutilizing BLAST and Gapped BLAST programs, the default parameters of therespective programs (e.g., BLASTX and BLASTN) may be used. Seehttp://www.ncbi.nlm.nih.gov.

In another preferred embodiment, an isolated nucleic acid molecule ofthe invention comprises a nucleic acid molecule which is the complementof a nucleotide sequence as of the present invention, such as forinstance the sequence shown in SEQ ID NO: 1. A nucleic acid molecule,which is complementary to a nucleotide sequence disclosed herein, is onethat is sufficiently complementary to a nucleotide sequence shown in SEQID NO:1 such that it may hybridize to said nucleotide sequence therebyforming a stable duplex.

In a further preferred embodiment, a nucleic acid of the invention asshown in SEQ ID NO:1 or the complement thereof contains at least onemutation leading to a gene product with modified function/activity. Theat least one mutation may be introduced by methods described herein. Inone aspect, the at least one mutation leads to a GMS 01 protein whosefunction compared to the wild type counterpart is completely orpartially destroyed. Methods for introducing such mutations are wellknown in the art.

The term “reduction” of activity as used herein encompasses decreasingactivity of one or more polypeptides in the producing organism, which inturn are encoded by the corresponding polynucleotides described herein.There are a number of methods available in the art to accomplishreduction of activity of a given protein, in this case the GMS 01protein. In general, the specific activity of a protein may be decreasedor the copy number of the protein may be decreased.

To facilitate such a decrease, the copy number of the genescorresponding to the polynucleotides described herein may be decreased,such as for instance by underexpression or disruption of a gene. A geneis said to be “underexpressed” if the level of transcription of saidgene is reduced in comparison to the wild type gene. This may bemeasured by for instance Northern blot analysis quantifying the amountof mRNA as an indication for gene expression. As used herein, a gene isunderexpressed if the amount of generated mRNA is decreased by at least1%, 2%, 5% 10%, 25%, 50%, 75%, 100%, 200% or even more than 500%,compared to the amount of mRNA generated from a wild-type gene.Alternatively, a weak promoter may be used to direct the expression ofthe polynucleotide. In another embodiment, the promoter, regulatoryregion and/or the ribosome binding site upstream of the gene can bealtered to achieve the down-expression. The expression may also bereduced by decreasing the relative half-life of the messenger RNA. Inanother embodiment, the activity of the polypeptide itself may bedecreased by employing one or more mutations in the polypeptide aminoacid sequence, which decrease the activity. For example, altering theaffinity of the polypeptide for its corresponding substrate may resultin reduced activity. Likewise, the relative half-life of the polypeptidemay be decreased. In either scenario, that being reduced gene expressionor reduced activity, the reduction may be achieved by altering thecomposition of the cell culture media and/or methods used for culturing.“Reduced expression” or “reduced activity” as used herein means adecrease of at least 5%, 10%, 25%, 50%, 75%, 100%, 200% or even morethan 500%, compared to a wild-type protein, polynucleotide, gene; or theactivity and/or the concentration of the protein present before thepolynucleotides or polypeptides are reduced. The activity of the GMS 01protein may also be reduced by contacting the protein with a specific orgeneral inhibitor of its activity. The terms “reduced activity”,“decreased or abolished activity” are used interchangeably herein.

Another aspect of the invention pertains to vectors, containing anucleic acid encoding a protein according to the invention or afunctional equivalent or portion thereof. As used herein, the term“vector” refers to a nucleic acid molecule capable of transportinganother nucleic acid to which it has been linked. One type of vector isa “plasmid”, which refers to a circular double stranded DNA loop intowhich additional DNA segments may be ligated. Another type of vector isa viral vector, wherein additional DNA segments may be ligated into theviral genome. Certain vectors are capable of autonomous replication in ahost cell into which they are introduced (e.g., bacterial vectors havinga bacterial origin of replication). Other vectors are integrated intothe genome of a host cell upon introduction into the host cell, andthereby are replicated along with the host genome.

Moreover, certain vectors are capable of directing the expression ofgenes to which they are operatively linked. Such vectors are referred toherein as “expression vectors”. In general, expression vectors ofutility in recombinant DNA techniques are often in the form of plasmids.The terms “plasmid” and “vector” can be used interchangeably herein asthe plasmid is the most commonly used form of vector. However, theinvention is intended to include such other forms of expression vectors,such as viral vectors (e.g., replication defective retroviruses,adenoviruses and adeno-associated viruses), which serve equivalentfunctions.

The recombinant vectors of the invention comprise a nucleic acid of theinvention in a form suitable for expression of the nucleic acid in ahost cell, which means that the recombinant expression vector includesone or more regulatory sequences, selected on the basis of the hostcells to be used for expression, which is operatively linked to thenucleic acid sequence to be expressed. Within a recombinant expressionvector, “operatively linked” is intended to mean that the nucleotidesequence of interest is linked to the regulatory sequence(s) in a mannerwhich allows for expression of the nucleotide sequence (e.g., in an invitro transcription/translation system or in a host cell when the vectoris introduced into the host cell). The term “regulatory sequence” isintended to include promoters, enhancers and other expression controlelements (e.g., attenuator). Such regulatory sequences are described,for example, in Goeddel; Gene Expression Technology: Methods inEnzymology 185, Academic Press, San Diego, Calif. (1990). Regulatorysequences include those which direct constitutive or inducibleexpression of a nucleotide sequence in many types of host cells andthose which direct expression of the nucleotide sequence only in acertain host cell (e.g. tissue-specific regulatory sequences). It willbe appreciated by those skilled in the art that the design of theexpression vector can depend on such factors as the choice of the hostcell to be transformed, the level of expression of protein desired, etc.The expression vectors of the invention may be introduced into hostcells to thereby produce proteins or peptides, encoded by nucleic acidsas described herein, including, but not limited to, mutant proteins,fragments thereof, variants or functional equivalents thereof, andfusion proteins, encoded by a nucleic acid as described herein, e.g.,GMS 01 proteins, mutant forms of GMS 01 proteins, fusion proteins andthe like.

The recombinant expression vectors of the invention may be designed forexpression of GMS 01 proteins in a suitable microorganism. For example,a protein according to the invention may be expressed in bacterial cellssuch as strains belonging to the genera Gluconobacter, Gluconacetobacteror Acetobacter. Expression vectors useful in the present inventioninclude chromosomal-, episomal- and virus-derived vectors e.g., vectorsderived from bacterial plasmids, bacteriophage, and vectors derived fromcombinations thereof, such as those derived from plasmid andbacteriophage genetic elements, such as cosmids and phagemids.

The DNA insert may be operatively linked to an appropriate promoter,which may be either a constitutive or inducible promoter. The skilledperson will know how to select suitable promoters. The expressionconstructs may contain sites for transcription initiation, termination,and, in the transcribed region, a ribosome binding site for translation.The coding portion of the mature transcripts expressed by the constructsmay preferably include an initiation codon at the beginning and atermination codon appropriately positioned at the end of the polypeptideto be translated.

Vector DNA may be introduced into suitable host cells via conventionaltransformation or transfection techniques. As used herein, the terms“transformation”, “transconjugation” and “transfection” are intended torefer to a variety of art-recognized techniques for introducing foreignnucleic acid (e.g., DNA) into a host cell, including calcium phosphateor calcium chloride co-precipitation, DEAE-dextran-mediatedtransfection, transduction, infection, lipofection, cationiclipidmediated transfection or electroporation. Suitable methods fortransforming or transfecting host cells may be found in Sambrook, et al.(supra), Davis et al., Basic Methods in Molecular Biology (1986) andother laboratory manuals.

In order to identify and select cells which have integrated the foreignDNA into their genome, a gene that encodes a selectable marker (e.g.,resistance to antibiotics) is generally introduced into the host cellsalong with the gene of interest. Preferred selectable markers includethose that confer resistance to drugs, such as kanamycin, tetracycline,ampicillin and streptomycin. A nucleic acid encoding a selectable markeris preferably introduced into a host cell on the same vector as thatencoding a protein according to the invention or can be introduced on aseparate vector such as, for example, a suicide vector, which cannotreplicate in the host cells. Cells stably transfected with theintroduced nucleic acid can be identified by drug selection (e.g., cellsthat have incorporated the selectable marker gene will survive, whilethe other cells die).

The invention provides also an isolated polypeptide having the aminoacid sequence shown in SEQ ID NO:2 or an amino acid sequence obtainableby expressing a polynucleotide of the present invention, such as forinstance a polynucleotide sequence shown in SEQ ID NO:1 in anappropriate host.

Polypeptides according to the invention may contain only conservativesubstitutions of one or more amino acids in the amino acid sequencerepresented by SEQ ID NO:2 or substitutions, insertions or deletions ofnon-essential amino acids. Accordingly, a non-essential amino acid is aresidue that may be altered in the amino acid sequences shown in SEQ IDNO:2 without substantially altering the biological function. Forexample, amino acid residues that are conserved among the proteins ofthe present invention, are predicted to be particularly unamenable toalteration. Furthermore, amino acids conserved among the proteinsaccording to the present invention and other GMS 01 proteins are notlikely to be amenable to alteration.

The term “conservative substitution” is intended to mean that asubstitution in which the amino acid residue is replaced with an aminoacid residue having a similar side chain. These families are known inthe art and include amino acids with basic side chains (e.g., lysine,arginine and histidine), acidic side chains (e.g., aspartic acid,glutamic acid), uncharged polar side chains (e.g., glycine, asparagine,glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains(e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine,methionine, tryptophan), beta-branched side chains (e.g., threonine,valine, isoleucine) and aromatic side chains (e.g., tyrosine,phenylalanine, tryptophan, histidine).

As mentioned above, the polynucleotides of the invention may be utilizedin the genetic engineering of a suitable host cell to make it better andmore efficient in the bioconversion of a carbon source such as e.g.glucose to biomass, i.e. reduction of carbon source diversion throughoutthe bioconversion process.

According to the invention a genetically engineered/recombinant hostcell (also referred to as recombinant cell or transformed cell) may beproduced carrying such a modified polynucleotide wherein the function ofthe linked protein is significantly modified in comparison to awild-type cell such that the yield and/or productivity of biomass from acarbon source such as e.g. glucose is improved. The host cell may beselected from a microorganism capable of converting a given carbonsource such as e.g. glucose into biomass, in particular Gluconobacteroxydans, preferably G. oxydans DSM 17078.

A “transformed cell” or “recombinant cell” is a cell into which (or intoan ancestor of which) has been introduced, by means of recombinant DNAtechniques, a nucleic acid according to the invention, or wherein theactivity of the GMS 01 protein has been decreased or abolished. Suitablehost cells include cells of microorganisms capable of converting a givencarbon source such as e.g. glucose into biomass. In particular, theseinclude strains from the genera Pseudomonas, Pantoea, Escherichia,Corynebacterium, Ketogulonicigenium and acetic acid bacteria like e.g.,Gluconobacter, Acetobacter or Gluconacetobacter, preferably Acetobactersp., Acetobacter aceti, Gluconobacter frateurii, Gluconobacter cerinus,Gluconobacter thailandicus, Gluconobacter oxydans, more preferably G.oxydans, most preferably G. oxydans DSM 17078.

To improve the biomass production of a certain recombinant host cell,i.e. reduce the diversion of carbon substrates throughout thebioconversion process, GMS 01 gene expression may be inhibited in thatorganism for instance by targeting nucleotide sequences complementary tothe regulatory region of a GMS 01 nucleotide sequence (e.g., a GMS 01promoter and/or enhancers) to form triple helical structures thatprevent transcription of a GMS 01 gene in target cells. See generally,Helene, C. (1991) Anticancer Drug Des. 6 (6): 569-84; Helene, C. et al.(1992) Ann. N.Y. Acad. Sci. 660: 27-36; and Maher, L. J. (1992)Bioassays 14 (12): 807-15.

Inhibition or prevention of gene expression may also be achieved bymodifying the GMS 01 gene, e.g., by introducing one or more mutationsinto the GMS 01 gene wherein said modification leads to a GMS 01 proteinwith a function which is significantly decreased in comparison to thewild-type protein.

Therefore, in one other embodiment, the polynucleotide carrying the atleast one mutation is derived from a polynucleotide as represented bySEQ ID NO:1 or equivalents thereof.

A mutation as used herein may be any mutation leading to a lessfunctional or unstable polypeptide, e.g. less functional or unstable GMS01 gene products. This may include for instance an alteration in thegenome of a microorganism, which interferes with the synthesis of GMS 01or leads to the expression of a GMS 01 protein with an altered aminoacid sequence whose function compared with the wild type counterparthaving a non-altered amino acid sequence is completely or partiallydestroyed. The interference may occur at the transcriptional,translational or post-translational level.

The alteration in the genome of the microorganism may be obtained e.g.by replacing through a single or double crossover recombination a wildtype DNA sequence by a DNA sequence containing the alteration. Forconvenient selection of transformants of the microorganism with thealteration in its genome the alteration may, e.g. be a DNA sequenceencoding an antibiotic resistance marker or a gene complementing apossible auxotrophy of the microorganism. Mutations include, but are notlimited to, deletion-insertion mutations.

An alteration in the genome of the microorganism leading to a less ornon-functional polypeptide may also be obtained by randomly mutagenizingthe genome of the microorganism using e.g. chemical mutagens, radiationor transposons and selecting or screening for mutants which are betteror more efficient producers of biomass. Standard methods for screeningand selection are known to the skilled person.

In a specific embodiment, it is desired to knockout the GMS 01 gene ofthe present invention, i.e., wherein its gene expression is artificiallysuppressed in order to improve the yield and/or efficiency of biomassproduction when introduced into a suitable host cell. Methods ofproviding knockouts as well as microorganisms carrying such suppressedgenes are well known in the art. The suppression of the endogenous GMS01 gene may be induced by deleting at least a part of the gene or theregulatory region thereof. As used herein, “suppression of the geneexpression” includes complete and partial suppression, as well assuppression under specific conditions and also suppression of theexpression of either one of the two alleles.

In order to create a knockout microorganism in which the expression ofthe GMS 01 gene is artificially suppressed, first the GMS 01 gene may becloned and then a vector for homologous recombination may be constructedby using the gene to inactivate the endogenous GMS 01 gene in the targetmicroorganism. The vector for homologous recombination then contains anucleic acid sequence designed to inactivate the endogenous GMS 01 genein the target microorganism. Such a nucleic acid may be for instance anucleic acid sequence of the GMS 01 gene or the regulatory regionthereof, such as the existing flanking region of the gene to beinactivated (in cis), or existing separately (in trans), containing atleast a partial deletion, or alternatively it may be a nucleic acidsequence of the GMS 01 gene or the regulatory region thereof containingother genes. A gene which can also function as a marker is preferablyselected as the gene to be inserted into the GMS 01 gene or theregulatory region thereof. The insert genes to be used include forinstance drug-resistance genes as defined above. There is no particularlimitation on the position where the genes may be inserted in the GMS 01gene, as long as the insertion at that position results in thesuppression of the expression of the endogenous GMS 01 gene in thetarget. To avoid polar effects of the insertion, in-frame silentdeletions can be introduced by using, for example, the sacB system orlong-flanking homology PCR. These techniques are well known to theperson skilled in the art.

The aforementioned mutagenesis strategies for GMS 01 proteins may resultin increased yield and/or production of biomass. This list is not meantto be limiting; variations on these mutagenesis strategies will bereadily apparent to one of ordinary skill in the art. By thesemechanisms, the nucleic acid and protein molecules of the invention maybe utilized to generate microorganisms such as Gluconobacter oxydans orrelated strains of bacteria expressing mutated GMS 01 nucleic acid andprotein molecules such that the yield, efficiency and/or productivity ofbiomass production from a carbon source such as e.g. glucose isimproved.

Biomass concentration can be measured using several methods known to theperson skilled in the art, such as e.g. measuring the optical density ofthe respective cell suspensions at for instance a wavelength of 600 nm(OD₆₀₀), or measuring either the wet- or dry-cell mass concentration orby counting the numbers of cells of the respective cell suspension. Suchmethods of measurement are known in the art. Thus, the cell dry weight(CDW) [g/l] may be for instance measured on a dried and tarednitrocellulose filter with a pore size of e.g. 0.45 μm on which theculture broth is filtrated. After washing the filter with water, theweight of the dried filter is again determined and the CDW calculated asfollows:CDW=m(dried filter after broth filtration)−m(dried filter before brothfiltration)

In one aspect of the invention, microorganisms (in particular from thegenera of Gluconobacter, Gluconacetobacter and Acetobacter) are providedthat are able to perform such improved bioconversion. When measured by amethod as described herein these organisms were found to have animproved capability to produce biomass from a carbon source such as e.g.glucose. Such may be achieved by increasing the activity of a GMSpolypeptide, preferably a GMS 01 polypeptide. The yield of biomassproduced from a carbon source, such as for instance glucose, whenmeasured according to this method after an incubation period of 24 hoursmay be about 0.1 g or more dry biomass/g carbon source, preferably about0.2 g or more dry biomass/g carbon source, or even about 0.3 g or moredry biomass/g carbon source, such as for instance about 0.4 g, 0.5 g,0.6 g, 0.7 g, 0.8 g or 1.0 g or more dry biomass/g carbon source.Preferably, the carbon source is glucose.

The recombinant microorganism carrying e.g. a modified GMS 01 gene andwhich is able to produce biomass from a carbon source such as e.g.glucose in significantly higher yield, productivity, and/or efficiencymay be cultured in an aqueous medium supplemented with appropriatenutrients under aerobic conditions. The cultivation may be conducted inbatch, fed-batch, semi-continuous or continuous mode. The cultivationperiod may vary depending on for instance the host, pH, temperature andnutrient medium to be used, and is preferably about 1 to about 10 dayswhen run in batch or fed-batch mode. The cultivation may be conducted atfor instance a pH of about 4.0 to about 9.0, preferably about 5.0 toabout 8.0. The preferred temperature range for carrying out thecultivation is from about 13° C. to about 36° C., preferably from about18° C. to about 33° C. Usually, the culture medium may contain besidese.g. D-glucose as main carbon source other assimilable carbon sources,e.g., glycerol, D-mannitol, D-sorbitol, L-sorbose, erythritol, ribitol,xylitol, arabitol, inositol, dulcitol, D-ribose, D-fructose, sucrose andethanol, preferably D-sorbitol, D-mannitol, D-fructose, glycerol andethanol; and digestible nitrogen sources such as organic substances,e.g., peptone, yeast extract, baker's yeast, urea, amino acids, and cornsteep liquor. Various inorganic substances may also be used as nitrogensources, e.g., nitrates and ammonium salts. Furthermore, the culturemedium usually may contain inorganic salts, e.g., magnesium sulfate,manganese sulfate, potassium phosphate, and calcium carbonate.

The nucleic acid molecules, polypeptides, vectors, primers, andrecombinant microorganisms described herein may be used in one or moreof the following methods: identification of Gluconobacter oxydans andrelated organisms; mapping of genomes of organisms related toGluconobacter oxydans; identification and localization of Gluconobacteroxydans sequences of interest; evolutionary studies; determination ofGMS 01 protein regions required for function; modulation of a GMS 01protein activity or function; modulation of the activity of a GMSpathway; and modulation of cellular production of biomass from a carbonsource such as e.g. glucose.

The invention provides methods for screening molecules which modulatethe activity of a GMS 01 protein, either by interacting with the proteinitself or a substrate or binding partner of the GMS 01 protein, or bymodulating the transcription or translation of a GMS 01 nucleic acidmolecule of the invention. In such methods, a microorganism expressingone or more GMS 01 proteins of the invention is contacted with one ormore test compounds, and the effect of each test compound on theactivity or level of expression of the GMS 01 protein is assessed.

The biological, enzymatic or other activity of GMS proteins can bemeasured by methods well known to a skilled person, such as, forexample, by incubating a cell fraction containing the GMS 01 protein inthe presence of its substrate, electron acceptor(s) or donor(s)including phenazine methosulfate (PMS), dichlorophenol-indophenol(DCIP), NAD, NADH, NADP, NADPH, which consumption can be directly orindirectly measured by photometric, colorimetric or fluorimetricmethods, and other inorganic components which might be relevant for thedevelopment of the activity. Thus, for example, the activity ofmembrane-bound D-glucose dehydrogenase can be measured in an assay wheremembrane fractions containing this enzyme are incubated in the presenceof phosphate buffer at pH 6, D-glucose and the artificial electronacceptors DCIP and PMS. The rate of consumption of DCIP can be measuredat 600 nm, and is directly proportional to the D-glucose dehydrogenaseactivity present in the membrane fraction.

Thus, the present invention is directed to the use of a polynucleotide,polypeptide, vector, primer and recombinant microorganism as describedherein in the production of biomass, i.e., the bioconversion of a carbonsource such as e.g. glucose into biomass. In a preferred embodiment, amodified polynucleotide, polypeptide, vector and recombinantmicroorganism as described herein is used for improving the yield,productivity, and/or efficiency of said biomass production.

The terms “production” or “productivity” are art-recognized and includethe amount of biomass formed within a given time and a given cultivationvolume (e.g., kg product per hour per liter) from a given amount orconcentration of a carbon source such as e.g. glucose. The term“efficiency of production” includes the time required for a particularlevel of production to be achieved (for example, how long it takes forthe cell to attain a particular rate of output of a product). The term“yield” is art-recognized and includes the efficiency of the conversionof the carbon source into biomass. This is generally written as, forexample, kg biomass per kg carbon source. By “increasing the yieldand/or production of biomass” it is meant that in a given amount ofculture over a given amount of time the biomass is increased. Bymeasuring the increase in biomass- and decrease in carbon sourceconcentration in a growing culture, one can calculate the yield ofbiomass on consumed carbon source; i.e. the weight of biomass obtainedby bioconverting a determined weight of carbon source such as e.g.glucose, defined as kg biomass per kg carbon source consumed. Todetermine the consumption of carbon source, the residual amount ofcarbon source in the growth medium can be measured by methods well knownin the art (e.g. HPLC). The increase of biomass can be measured bymethods well known in the art (e.g. optical density at 600 nm, ormeasurement of dry weight of a sample).

The terms “biosynthesis” or a “biosynthetic pathway” are art-recognizedand include the synthesis of a compound/product, preferably an organiccompound, by a cell from intermediate compounds in what may be amultistep and highly regulated process. The term “bioconversion” isart-recognized and includes the conversion of a carbon source such ase.g. glucose into a product, i.e. biomass, by means of one or morebiosynthetic step(s) which involve one or more enzyme(s) and/ortransporter(s). The language “metabolism” is art-recognized and includesthe totality of the biochemical reactions that take place in anorganism. The metabolism of a particular compound, then, (e.g., themetabolism of an amino acid such as glycine) comprises the overallbiosynthetic, modification, and degradation pathways in the cell relatedto this compound. The language “transport” or “import” is art-recognizedand includes the facilitated movement of one or more molecules across acellular membrane through which the molecule would otherwise either beunable to pass or be passed inefficiently.

In one preferred embodiment, the present invention is related to aprocess for the production of biomass from a carbon source such as e.g.glucose wherein a modified polynucleotide sequence as described above isintroduced into a suitable microorganism and the recombinantmicroorganism is cultured under conditions that allow the production ofbiomass in high productivity, yield, and/or efficiency.

Recombinant microorganisms according to the present invention carryinge.g. a modified GMS gene, in particular a modified GMS 01 gene, andwhich are able to produce biomass from a carbon source such as e.g.glucose in significantly higher yield, productivity, and/or efficiencymay advantageously be used in a number of applications. One particularlysuited application is a method for the production of Vitamin C and/orintermediates thereof such like 2-keto-L-gulonic acid (2-KGA).

Thus, it is an aspect of the present invention to provide a process forthe production of Vitamin C and/or 2-KGA wherein a nucleotide accordingto the invention or a modified polynucleotide sequence as describedabove is introduced into a suitable microorganism as described abovewherein a suitable carbon source such as e.g. glucose is efficientlyconverted into biomass, the recombinant microorganism is cultured underconditions that allow the production of Vitamin C and/or 2-KGA in highproductivity, yield, and/or efficiency, the produced fermentationproduct is isolated from the culture medium and optionally furtherpurified.

The carbon sources used for the production of (1) biomass and (2)Vitamin C and/or 2-KGA may be the same or may differ. In one preferredembodiment, the carbon source(s) used for the production of biomass isdifferent from the carbon source(s) used for the direct production ofVitamin C and/or 2-KGA. These two different carbon sources may be usedsimultaneously or sequentially, wherein a first carbon source would beused for the production of biomass, and this biomass would then be usedto convert a second carbon source into Vitamin C and/or 2-KGA.

A suitable carbon source that can be converted directly into Vitamin Cand/or 2-KGA may be selected from the D-glucose or D-sorbitolmetabolization pathway such as, for example, D-glucose, D-sorbitol,L-sorbose, L-sorbosone, D-gluconate, 2-keto-D-gluconate or2,5-diketo-gluconate or mixtures thereof. Preferably, the substrate isselected from for instance D-glucose, D-sorbitol, L-sorbose, L-sorbosoneor mixtures thereof, more preferably from D-glucose, D-sorbitol,L-sorbose or mixtures thereof, and most preferably from D-sorbitol,L-sorbose or mixtures thereof.

Vitamin C as used herein may be any chemical form of L-ascorbic acidfound in aqueous solutions, such as for instance undissociated, in itsfree acid form or dissociated as an anion. The solubilized salt form ofL-ascorbic acid may be characterized as the anion in the presence of anykind of cations usually found in fermentation supernatants, such as forinstance potassium, sodium, ammonium, or calcium. Also included may beisolated crystals of the free acid form of L-ascorbic acid. On the otherhand, isolated crystals of a salt form of L-ascorbic acid are called bytheir corresponding salt name, i.e. sodium ascorbate, potassiumascorbate, calcium ascorbate and the like.

Conversion of a suitable carbon source into Vitamin C and/or 2-KGA inconnection with the above process using a microorganism means that theconversion of the carbon source resulting in Vitamin C and/or 2-KGA isperformed by the microorganism, i.e. the carbon source may be directlyconverted into Vitamin C and/or 2-KGA. Said microorganism is culturedunder conditions which allow such conversion from said carbon source asit is known for the skilled person.

A medium as used herein for the above process using a microorganism maybe any suitable medium for the production of Vitamin C and/or 2-KGA.Typically, the medium is an aqueous medium comprising for instancesalts, substrate(s), and a certain pH.

The term “direct conversion” and the like is intended to mean that amicroorganism is capable of the conversion of a certain carbon sourceinto the specified product by means of one or more biological conversionsteps, without the need of any additional chemical conversion step. Forinstance, the term “direct conversion of D-sorbitol into Vitamin C” isintended to describe a process wherein a microorganism is producingVitamin C and wherein D-sorbitol is offered as a carbon source withoutthe need of an intermediate chemical conversion step. A singlemicroorganism capable of directly fermenting Vitamin C is preferred.

This invention is further illustrated by the following examples whichshould not be construed as limiting. The contents of all references,patent applications, patents and published patent applications, citedthroughout this application are hereby incorporated by reference.

EXAMPLES Example 1 Analytical Methods for Biomass and GlucoseDetermination

For determination of biomass production, cells of G. oxydans were grownat 27° C. for 3 days on MB agar, containing 25 g/l mannitol, 5.0 g/lyeast extract (Difco), 3.0 g/l Bactopeptone (Difco) and 15 g/l agar.Cells were resuspended in 10% glycerol (10 ml per plate) and 1 mlaliquots were stored at −80° C.

A baffled 500 ml shake flask with 100 ml medium No. 5 containing 50 g/lD-glucose, 0.5 g/l glycerol, 15 g/l yeast extract (Difco), 2.5 g/lMgSO₄.7H₂O, 0.3 g/l KH₂PO₄, 15 g/l CaCO₃ and 1 drop antifoam wasinoculated with a 1 ml aliquot and incubated at 30° C. and 180 rpm in ashaker for 48 h. The optical density at 600 nm (OD₆₀₀) was determinedusing a Spectronic 4001/N spectrophotometer and an identical medium No.5 flask was then inoculated with this culture, such that the start OD₆₀₀in the second flask was 0.25. This flask was then further incubated at30° C., 180 rpm for another 60 h with samples of 3 ml taken every 12 hfor analysis of biomass and glucose concentrations as follows:

Production of biomass was determined via measurement of the dry weightof the sample. Reaction tubes were pre-dried at 40° C. under vacuum for48 h and the weight of the empty tubes measured [w1]. The sample wasadded and the weight of the full tube determined [w2]. 0.1 ml 18.5% HClwas added to dissolve the CaCO₃. The tubes were subsequently centrifugedfor 3 min at 13000 rpm. The supernatant was discarded, 0.5 ml of waterwas added and the pellet was resuspended. The tube was centrifuged againfor 3 min at 13000 rpm and the supernatant was discarded. The pellet wasdried at 40° C. under vacuum for 48 h and the tube containing the pelletagain weighted [w3]. The concentration of biomass [B] in the sample wascalculated as follows:(w3−w1)/(w2−w1)×1000=concentration of biomass [g/kg]

The amount or concentration of glucose [G] was measured by HPLC on anHewlett-Packard 1100 instrument using an Aminex-HPX-78H (300×7.8 mm)column (Biorad, Reinach, Switzerland) combined with aLiChrospher-100-RP18, 5 μm precolumn (Merck, Darmstadt, Germany). Themobile phase was 0.004 M sulfuric acid, pumped at a flow rate of 0.6mL/min. A refractive index detector was used to monitor the signal.External standard calibration was applied based on peak areas.

The yield, i.e. the amount of biomass (dry weight) obtained fromconversion of D-glucose [g biomass/g D-glucose] after a given time wascalculated as follows, wherein (t1) defines the concentration of biomassand D-glucose, respectively, measured during or at the end ofcultivation, for instance after 24 or 48 h, and (t0) defines therespective concentrations at the beginning of the cultivation (seeabove):[B(t1)−B(t0)]/[G(t1)−G(t0)]=yield of biomass on consumed glucose [g/g]

The volumetric biomass productivity [g/kg/h], i.e. the amount of biomassproduced per liter of culture and per time unit was calculated asfollows:[B(t1)−B(t0)]/(t0−t1)=volumetric biomass productivity [g/kg/h]

Example 2 Preparation of Chromosomal DNA and Amplification of DNAFragment by PCR

Chromosomal DNA of Gluconobacter oxydans DSM 17078 was prepared from thecells cultivated at 30° C. for 1 day in mannitol broth (MB) liquidmedium consisting of 25 g/l mannitol, 5 g/l of yeast extract (Difco),and 3 g/l of Bactopeptone (Difco) by the method described by Sambrook etal (1989) “Molecular Cloning: A Laboratory Manual/Second Edition”, ColdSpring Harbor Laboratory Press).

A DNA fragment was prepared by PCR with the chromosomal DNA preparedabove and a set of primers, Pf (SEQ ID NO:3) and Pr (SEQ ID NO:4). Forthe reaction, the Expand High Fidelity PCR kit (Roche Diagnostics) and10 ng of the chromosomal DNA was used in total volume of 100 μlaccording to the supplier's instruction to have the PCR productcontaining GMS 01 DNA sequence (SEQ ID NO:1). The PCR product wasrecovered from the reaction and its correct sequence confirmed.

Example 3 Disruption of the GMS 01 Gene in G. Oxydans DSM 17078

The PCR product obtained in Example 2 was cloned in an E. coli vectorpCR2.1-TOPO and used to transform E. coli TG1 to have a Apr transformantcarrying pCR2.1-GMS 01. Then, Km^(r) cassette isolated from pUC-4K(Amersham Bioscience, accession No. X06404) was inserted into one of therestriction site of the target gene with ligase and the resultingligation product was used to transform E. coli TG1 to have Apr Kmrtransformant carrying pCR2.1-GMS 01::Km. The pCR2.1-GMS 01::Km plasmidprepared from the transformant was digested by two restriction enzymesselected from the multi-cloning site of the vector part to isolate a DNAfragment containing GMS 01::Km. The resulting DNA fragment was used totransform G. oxydans DSM 17078 by electroporation to have the genedisruptant, G. oxydans DSM 17078-GMS 01::Km.

Example 4 Production of Biomass from D-Glucose in Liquid Cultures

Cells of G. oxydans DSM 17078 and G. oxydans DSM 17078-GMS 01::Km werecultivated as described above and the yield of produced biomass andvolumetric biomass productivity determined (see Example 1), wherein(t1)=24 h. The results are depicted in Table 1.

TABLE 1 Production of biomass from D-glucose Yield of biomass Volumetricbiomass on consumed productivity Strain glucose [g/g] [g/kg/h] G.oxydans DSM 17078 0.032 0.052 G. oxydans DSM 17078-GMS 0.24 0.109 01::Km

Example 5 Presence of the GMS 01 Gene and Equivalents in Other Organisms

The presence of SEQ ID NO:1 and/or equivalents in other organisms thanthe ones disclosed herein before, e.g. organisms as mentioned in Table2, may be determined by a simple DNA hybridization experiment.

Strains of Acetobacter aceti subsp. xylinum IFO 13693 and IFO 13773 aregrown at 27° C. for 3 days on No. 350 medium containing 5 g/lBactopeptone (Difco), 5 g/l yeast extract (Difco), 5 g/l glucose, 5 g/lmannitol, 1 g/l MgSO₄.7H₂O, 5 ml/l ethanol, and 15 g/l agar. All otherAcetobacter, Gluconacetobacter and all Gluconobacter strains are grownat 27° C. for 3 days on mannitol broth (MB) agar medium containing 25g/l mannitol, 5 g/l yeast extract (Difco), 3 g/l Bactopeptone (Difco),and 18 g/l agar (Difco). E. coli K-12 is grown on Luria Broth agarmedium. The other strains are grown on medium recommended by thesuppliers or according to methods known in the art. Genomic DNA isextracted as described by e.g. Sambrook et al., 1989, “MolecularCloning: A Laboratory Manual/Second Edition”, Cold Spring HarborLaboratory Press) from a suitable organism as, e.g. mentioned in Table2.

Genomic DNA preparations are digested with restriction enzymes such asEcoRI or HindIII, and 1 μg of the DNA fragments are separated by agarosegel electrophoresis (1% agarose). The gel is treated with 0.25 N HCl for15 min and then 0.5 N NaOH for 30 min, and then blotted ontonitrocellulose or a nylon membrane with Vacuum Blotter Model 785(BIO-RAD Laboratories AG, Switzerland) according to the instruction ofthe supplier. The resulting blot is then brought into contact/hybridizedwith a solution wherein the probe, such as e.g. a DNA fragment with SEQID NO:1 sequence or a DNA fragment containing the part or whole of theSEQ ID NO:1 sequence to detect positive DNA fragment(s) from a testorganism. A DIG-labeled probe, e.g. SEQ ID NO:1, may be preparedaccording to Example 1 by using the PCR-DIG labeling kit (RocheDiagnostics) and a set of primers, SEQ ID NO:3 and SEQ ID NO:4. A resultof such a blot is depicted in Table 2.

The hybridization may be performed under stringent or highly stringentconditions. A preferred, non-limiting example of such conditions arehybridization in 6× sodium chloride/sodium citrate (SSC) at about 45°C., followed by one or more washes in 1×SSC, 0.1% SDS at 50° C.,preferably at 55° C., more preferably at 60° C. and even more preferablyat 65° C. Highly stringent conditions include, for example, 2 h to 4days incubation at 42° C. in a solution such as DigEasyHyb solution(Roche Diagnostics GmbH) with or without 100 μg/ml salmon sperm DNA, ora solution comprising 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodiumcitrate), 0.02% sodium dodecyl sulfate, 0.1% N-lauroylsarcosine, and 2%blocking reagent (Roche Diagnostics GmbH), followed by washing thefilters twice for 5 to 15 min in 2×SSC and 0.1% SDS at room temperatureand then washing twice for 15-30 min in 0.5×SSC and 0.1% SDS or 0.1×SSCand 0.1% SDS at 65-68° C. To detect DNA fragments with lower identity tothe probe DNA, final washing steps can be done at lower temperaturessuch as 50-65° C. and for shorter washing time such as 1-15 min.

The genes corresponding to the positive signals within the respectiveorganisms shown in Table 2 can be cloned by a PCR method well known inthe art using genomic DNA of such an organism together with a suitableprimer set, such as e.g. SEQ ID NO:3 and SEQ ID NO:4 under conditions asdescribed in Example 1 or as follows: 5 to 100 ng of genomic DNA is usedper reaction (total volume 50 μl). Expand High Fidelity PCR system(Roche Diagnostics) can be used with reaction conditions consisting of94° C. for 2 min; 30 cycles of (i) denaturation step at 94° C. for 15sec, (ii) annealing step at 60° C. for 30 sec, (iii) synthesis step at72° C. for 0.5 to 5 min depending to the target DNA length (1 min/1 kb);extension at 72° C. for 7 min. Alternatively, one can perform a PCR withdegenerate primers, which can be synthesized based on SEQ ID NO:2 oramino acid sequences as consensus sequences selected by aligning severalamino acid sequences obtained by a sequence search program such asBLASTP (or BLASTX when nucleotide sequence is used as a “querysequence”) to find proteins having a similarity to the protein of SEQ IDNO:2. For PCR using degenerate primers, temperature of the secondannealing step (see above) can be lowered to 55° C., or even to 50-45°C. A result of such an experiment is shown in Table 2.

Samples of the PCR reactions are separated by agarose gelelectrophoresis and the bands are visualized with a transilluminatorafter staining with e.g. ethidium bromide, isolated from the gel and thecorrect sequence is confirmed.

Consensus sequences mentioned above might be amino acid sequencesbelonging to certain categories of several protein domain/familydatabases such as PROSITE (database of protein families and domains),COGs (Cluster of Ortholog Groups), CDD (Conserved Domain Databases),pfam (large collection of multiple sequence alignments and hidden Markovmodels covering many common protein domains and families). Once one canselect certain protein with identical/similar function to the protein ofthis invention from proteins containing domain or family of suchdatabases, corresponding DNA encoding the protein can be amplified byPCR using the protein sequence or its nucleotide sequence when it isavailable in public databases. Following organisms may further providegenes, which can be used as an alternative gene of this invention:Burkholderia xenovorans LB400, Acinetobacter calcoaceticus LMD79.41,Mesorhizobium loti MAFF303099, Sinorhizobium meliloti 1021.

Example 6 Disruption of the GMS 01 Gene and Equivalents in OtherOrganisms for Production of Biomass

In order to improve biomass production in a suitable microorganism froma carbon source such as e.g. glucose, the GMS 01 gene and equivalents ase.g. a PCR product obtained in Example 5, referred to hereafter as geneX, can be disrupted in accordance to the GMS 01 gene in G. oxydans DSM17078 (see Example 2) to generate a knockout mutant carrying GMS 01equivaltent gene::Km. Suitable host strains for generation of suchknockout mutants may be selected from e.g. Gluconobacter strains listedin Table 2, in particular e.g. G. oxydans IFO 3292, G. oxydans ATCC621H, G. oxydans IFO 12528, G. oxydans IFO 3291, G. oxydans IFO 3255, G.oxydans IFO 3244, G. cerinus IFO 3266, G. frateurii IFO 3260, G. oxydansIFO 3287, Acetobacter aceti subsp. orleanus IFO 3259, Acetobacter acetisubsp. xylinum IFO 13693, Acetobacter aceti subsp. xylinum IFO 13773 andAcetobacter sp. ATCC 15164.

The knockout mutant such as, e.g. a knockout mutant G. oxydans IFO3292-GMS 01 equivaltent gene::Km can be generated as follows: the PCRproduct obtained from G. oxydans IFO 3292 described in Example 5 iscloned in an E. coli vector pCR2.1-TOPO and used to transform E. coli TG1 to have a Ap^(r) transformant carrying pCR2.1-gene X. Then, Km^(r)cassette isolated from pUC-4K (Amersham Bioscience, accession No.X06404) is inserted into one of the restriction site of the target genewith ligase and the resulting ligation product is used to transform E.coli TG1 to have Ap^(r) Km^(r) transformant carrying pCR2.1-gene X::Km.The pCR2.1-gene X::Km plasmid prepared from the transformant is digestedby two restriction enzymes selected from the multi-cloning site of thevector part to isolate a DNA fragment containing gene X::Km. Theresulting DNA fragment is used to transform the host strain carrying theGMS 01 equivaltent gene by electroporation to have the gene disruptantcarrying GMS 01 equivaltent gene::Km.

Further modifications including genes involved in the conversion of acarbon source such as e.g. glucose into biomass within said strains maybe generated to improve biomass production within such strains.

Production of biomass from a carbon source such as e.g. glucose usingthe cells of the knockout mutant, e.g. G. oxydans IFO 3292-GMS 01equivaltent gene::Km, and the corresponding wild-type strain, e.g. G.oxydans IFO 3292, are performed according to Example 4.

In a reaction with 5% glucose as carbon source, the mutant strain canproduce at least more than 250% biomass compared to the wild-typestrain.

TABLE 2 Equivalents of the GMS 01 gene in other organisms. Signal SignalSignal Strain 1 2 3 G. oxydans DSM 17078 + + + G. oxydans IFO 3293 + + +G. oxydans IFO 3292 + + + G. oxydans ATCC 621H + + + G. oxydans IFO12528 + + + G. oxydans G 624 + + + G. oxydans T-100 + + + G. oxydans IFO3291 + + + G. oxydans IFO 3255 + + + G. oxydans ATCC 9937 + + + G.oxydans IFO 3244 + + + G. cerinus IFO 3266 + + + G. frateurii IFO3260 + + + G. oxydans IFO 3287 + + + Acetobacter aceti subsp. orleanusIFO 3259 + − + Acetobacier aceti subsp. xylinum IFO 13693 + − +Acetobacter aceti subsp. xylinum IFO 13773 + − + Acetobacter sp. ATCC15164 + − + G. thailandicus NBRC 100600 + + + Gluconacetobacterliquefaciens + + + ATCC 14835 Gluconacetobacter polyoxogenes + + + NBI1028 Gluconacetobacter diazotrophicus + + + ATCC 49037 Gluconacetobactereuropaeus DSM 6160 + + + Acetobacter aceti 1023 + − + Acetobacterpasteurianus NCI 1193 + − + Pseudomonas putida ATCC 21812 + − +Pseudomonas aeroginosa PAO1 + − + Pseudomonas fluorescens DSM 50106 +− + Pseudomonas syringae B728a + − + Rhodopseudomonas palustris CGA009 +− + Pantoea citrea 1056R + − + E. coli K12 + − + Saccharomycescerevisiae − − − Aspergillus niger − − − Mouse − − − Signal 1: Detectionof DN A on a blot with genomic DNA of different strains and SEQ ID NO: 1as labeled probe. Signal 2: Detection of DNA of different strains in aPCR reaction using primer pair SEQ ID NO: 3 and SEQ ID NO: 4. Signal 3:Detection of DNA of different strains in a PCR reaction using degenerateprimers. For more explanation refer to the text.

The invention claimed is:
 1. A process for the production of biomassfrom glucose comprising fermenting a recombinant microorganism selectedfrom Gluconobacter oxydans, wherein the endogenous gene encodingmembrane-bound glucose dehydrogenase is knocked-out in saidmicroorganism, said microorganism producing at least 75% more biomassfrom glucose than the wild-type microorganism capable to express anendogenous membrane-bound glucose dehydrogenase after 24 hours in abioconversion reaction comprising said fermenting and wherein thepolynucleotide encoding the knocked-out glucose dehydrogenase isselected from the group consisting of: (i) nucleotide sequence accordingto SEQ ID NO:1; (ii) nucleotide sequence encoding a polypeptideaccording to SEQ ID NO:2; and (iii) nucleotide sequence obtainable fromPCR using genomic DNA isolated from Gluconobacter capable to express anendogenous membrane-bound glucose dehydrogenase as template and primerset according to SEQ ID NO:3 and SEQ ID NO:4.
 2. A process according toclaim 1 wherein the microorganism has a reduced or abolishedoxidoreductase [EC 1] activity.
 3. A process for the production ofbiomass with a recombinant microorganism selected from Gluconobacteroxydans, wherein the endogenous gene encoding membrane-bound glucosedehydrogenase is knocked-out in said microorganism, said microorganismproducing at least 75% more biomass from glucose than the wild-typemicroorganism capable to express an endogenous membrane-bound glucosedehydrogenase after 24 hours in a bioconversion reaction comprising saidfermenting and wherein the polynucleotide encoding the knocked-outglucose dehydrogenase is selected from the group consisting of: (i)nucleotide sequence according to SEQ ID NO:1; (ii) nucleotide sequenceencoding a polypeptide according to SEQ ID NO:2; and (iii) nucleotidesequence obtainable from PCR using genomic DNA isolated fromGluconobacter capable to express an endogenous membrane-bound glucosedehydrogenase as template and primer set according to SEQ ID NO:3 andSEQ ID NO:4, wherein said microorganism is cultivated in an aqueousnutrient medium under conditions that allow production of biomass from acarbon source.
 4. A process for the production of a recombinantmicroorganism selected from Gluconobacter oxydans capable of producingat least 75% more biomass from glucose compared to the respectivewild-type microorganism after 24 hours in a bioconversion reaction,comprising the step of knocking-out the endogenous gene coding formembrane-bound glucose dehydrogenase and cultivation under suitableculture conditions for production of biomass, wherein the increase inbiomass is compared to the respective microorganism capable ofexpressing an endogenous membrane-bound glucose dehydrogenase, whereinthe polynucleotide encoding glucose dehydrogenase which is to beknocked-out is selected from the group consisting of: (i) nucleotidesequence according to SEQ ID NO:1; (ii) nucleotide sequence encoding apolypeptide according to SEQ ID NO:2; and (iii) nucleotide sequenceobtainable from PCR using genomic DNA isolated from Gluconobactercapable to express an endogenous membrane-bound glucose dehydrogenase astemplate and primer set according to SEQ ID NO:3 and SEQ ID NO:4.
 5. Arecombinant microorganism obtainable by the process according to claim4.
 6. A process according to claim 3 wherein the microorganism has areduced or abolished oxidoreductase [EC 1] activity.
 7. A processaccording to claim 3 wherein the carbon source is selected from thegroup consisting of glucose, sucrose, maltose, starch, cellulose,cellobiose, lactose, isomaltose, dextran, trehalose and mixturesthereof.
 8. The process according to claim 1 wherein said Gluconobacteroxydans is Gluconobacter oxydans DSM
 17078. 9. The process according toclaim 3 wherein said Gluconobacter oxydans is Gluconobacter oxydans DSM17078.